Key takeaways
- ~$400K+ annual WAC for Pompe ERT; Pombiliti + Opfolda est. $600K–$800K combined · manufacturer disclosures 2023
- Part B medical-benefit routing for all Pompe infusions; Opfolda (oral chaperone) routes separately to Part D · CMS HCPCS 2023
- 0 ICER cost-effectiveness reviews of Pompe ERT — a payer evidence gap · ICER Evidence Report database 2024
Every Pompe ERT is a high-cost Part B infusion, Pombiliti splits across two benefit categories, and no ICER review exists to set a value-based price.
All three US Pompe enzyme replacement therapies are intravenous infusions routed to the Medicare Part B medical benefit, carrying no patient out-of-pocket cost for most Medicare and Medicaid beneficiaries. Annual WAC is near $400,000 for the incumbent alglucosidase alfa (Lumizyme/Myozyme) and roughly $400,000–$450,000 for avalglucosidase alfa (Nexviazyme). The Pombiliti + Opfolda two-product regimen (cipaglucosidase alfa plus oral miglustat) is estimated at $600,000–$800,000 combined and is structurally different: the ERT routes to Part B while the oral chaperone Opfolda routes to Part D, creating a split-benefit coordination burden — two simultaneous prior authorisations across two benefit categories that some plans are not yet configured to process.
Payers treat alglucosidase alfa as the step-edit incumbent. Despite the COMET head-to-head data, many plans require documented inadequate response on Lumizyme (typically 12–18 months) before authorising a next-generation ERT — a friction point that slows switching more than any efficacy argument. And unlike myasthenia gravis, SMA, sickle cell disease, or ATTR amyloidosis, Pompe disease has never received an ICER cost-effectiveness review; payers apply analogies from Gaucher-disease ERT rather than a formal QALY-based benchmark, leaving a value-based-price evidence gap that outcomes research could fill.
US Pompe ERT payer status — pricing, routing and access, 2026
| Drug (Brand / INN) | Benefit Routing | Annual WAC (est.) | PA Criteria (Commercial) | Key Payer Dynamic |
|---|---|---|---|---|
| Nexviazyme (avalglucosidase alfa) | Medicare Part B (IV infusion) | ~$400K–$450K/yr | Confirmed GAA deficiency + symptomatic LOPD (FVC or 6MWT decline); some plans require inadequate Lumizyme response | COMET head-to-head data vs step-edit friction on switching |
| Pombiliti + Opfolda (cipaglucosidase + miglustat) | Split: ERT Part B + Opfolda Part D | ~$600K–$800K/yr combined | Confirmed Pompe + prior-ERT inadequate response; simultaneous PA for both products | Two-benefit coordination barrier; dual simultaneous PA |
| Lumizyme / Myozyme (alglucosidase alfa) | Medicare Part B (IV infusion) | ~$400K/yr | Confirmed Pompe + symptomatic LOPD; longest track record, easiest PA | Step-edit incumbent before next-gen ERT |
| ICER review (all agents) | — | No published Pompe review | — | Cost-effectiveness gap; payers apply Gaucher-ERT analogy |
Sources: Sanofi / Amicus pricing disclosures 2023; CMS HCPCS 2023 (Pombiliti / Opfolda routing); CVS Caremark Pompe ERT PA policy 2024; ICER Evidence Report database 2024 (Pompe absence confirmed). Non-PubMed payer sources, labeled.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How are the three US Pompe ERTs priced and routed across Medicare benefits? • Annual WAC for alglucosidase alfa, avalglucosidase alfa and the Pombiliti + Opfolda regimen • Part B medical-benefit routing for the infusions • the Part D routing of oral Opfolda
- What PA and step-edit criteria govern access to next-generation Pompe ERT? • GAA-confirmation and symptomatic-LOPD documentation requirements • inadequate-response-to-Lumizyme step-edits • the dual simultaneous PA for Pombiliti and Opfolda
- What is the HTA and cost-effectiveness picture for Pompe ERT — and what is missing? • The absence of an ICER Pompe review and the Gaucher-ERT analogy payers apply • the value-based-price evidence gap • where outcomes research could establish a benchmark
What's inside
-
1 · US Payer Landscape — Pompe ERT Coverage Architecture 4 pp
- Why all three US Pompe ERTs route to Medicare Part B, leaving most beneficiaries with no out-of-pocket cost.
- How Pombiliti + Opfolda's split-benefit design (Part B plus Part D) creates a dual prior-authorization burden.
-
2 · ERT Pricing & WAC Comparison 5 pp
- Why annual WAC ranges from about $400,000 for Lumizyme to $600,000-$800,000 for the Pombiliti + Opfolda regimen.
- How Nexviazyme's $400,000-$450,000 price sits between the incumbent and the newer two-product regimen.
-
3 · Benefit Routing — Part B Infusion & Pombiliti's Part D Split 5 pp
- Why the ERT component of Pombiliti routes to Part B while oral miglustat, Opfolda, routes to Part D.
- How this two-benefit structure requires simultaneous prior authorizations that some plans cannot yet process.
-
4 · PA Criteria & Step-Edit from Lumizyme 5 pp
- Why many plans require 12-18 months of documented inadequate response on Lumizyme before authorizing next-generation ERT.
- How this step-edit friction persists despite COMET head-to-head data favoring newer agents over the incumbent.
-
5 · The Missing ICER Review & Value-Based Price Gap 4 pp
- Why Pompe disease, unlike SMA or ATTR amyloidosis, has never received a formal ICER cost-effectiveness review.
- How payers instead apply cost-effectiveness analogies from Gaucher-disease ERT rather than a QALY-based Pompe benchmark.
-
6 · Outcomes-Based Contracting Outlook in Pompe 3 pp
- Why the absence of an ICER review leaves a value-based-price evidence gap that outcomes research could fill.
- How COMET trial data on avalglucosidase alfa could anchor a future outcomes-based contract against the Lumizyme incumbent.
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Pompe Payer & HTA is built for market access, HEOR, and pricing teams navigating high-cost ERT, split-benefit routing, and the ICER evidence gap in US Pompe. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, payer focus (pricing, routing, PA criteria), and commercial question.
- 2. Scoping callAXLRx analyst confirms payer scope, ERT comparators, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Pompe payer and HTA analysis is built from manufacturer pricing disclosures, CMS benefit-routing and HCPCS documentation, live commercial payer coverage and prior-authorisation policies, and a confirmed search of the ICER evidence-report database. Where no cost-effectiveness review exists, that absence is reported as a finding rather than filled with an estimate.
Key sources: Sanofi and Amicus Therapeutics pricing and access disclosures; CMS HCPCS and Part B / Part D benefit-routing documentation; CVS Caremark and OptumRx specialty-pharmacy Pompe ERT coverage policies; and the ICER Evidence Report database (Pompe absence confirmed, 2024).
- ERT WAC and next-generation pricing verified against Sanofi and Amicus manufacturer disclosures
- Pombiliti (Part B) plus Opfolda (Part D) split-benefit routing verified against CMS HCPCS and benefit-design documentation
- Step-edit and PA criteria verified against current commercial specialty-pharmacy coverage policies
- Absence of an ICER Pompe review verified against the ICER Evidence Report database
Frequently asked questions
Access How is Pompe enzyme replacement therapy covered and priced in the US?
All Pompe ERTs are intravenous infusions routed to the Medicare Part B medical benefit, with no patient out-of-pocket cost for most Medicare and Medicaid beneficiaries. Annual WAC is near $400,000 for both alglucosidase alfa (Lumizyme) and avalglucosidase alfa (Nexviazyme); the Pombiliti + Opfolda two-product regimen is estimated at $600,000–$800,000 combined, with the oral chaperone Opfolda routing separately to Part D — a split-benefit structure that can slow authorisation at plans without established workflows.
HTA Is there an ICER review or value-based price for Pompe ERT?
No. Unlike myasthenia gravis, SMA, sickle cell disease, or ATTR amyloidosis, Pompe disease has not received an ICER cost-effectiveness review. Payers apply analogies from Gaucher-disease ERT (comparable mechanism, cost, and rare-disease size), but no formal QALY-based value benchmark exists for Pompe, leaving a cost-effectiveness evidence gap that outcomes research could address.
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model, and a 10–15 slide PowerPoint readout deck. An optional 60-minute analyst readout call is included with all deliveries.